FDA Adverse Event Reporting System (FAERS)
Practical Insights to Avoid 483s

Wednesday, Dec. 18, 2019 • 1:30 p.m. - 3:00 p.m. EST

FDA’s increasing scrutiny of postmarket data means the agency is looking to industry to provide transparency into the impact of their drug products on patients.

Do you know how to avoid the pitfalls?

Fail to properly identify and report an adverse event with FDA’s Adverse Event Reporting System (FAERS) and you get a 483. Fail to report within the required time frame and you get another.

Beyond the regulatory compliance ramifications, the newly publicly available FAERS dashboard — openFDA — provides exposure to your reported events and can influence choices by healthcare providers and patients alike when it comes to choosing your therapeutic product.

Ricki Chase, M.S., Executive Director at Lachman Consultant Services and a former FDA investigator, explains how you can avoid 483s — among other serious issues.

Webinar Takeaways:

  • The difference between serious unexpected and serious expected events
  • The reportability time frame, when the clock starts and how to avoid being a late filer
  • Common FDA 483 observations related to adverse events and how to avoid them in your organization
  • What not to report under the FAERS program
  • How to handle combination product reporting
  • The value of data, how to access data and what it reveals or means

Ensure your company’s compliance by avoiding FAERS-related 483s. Join us by registering today.

Who Will Benefit

  • Industry Leads for Complaint Management
  • Industry Leads for Pharmacovigilance
  • Quality Managers
  • Quality Engineers
  • Complaint Analysts
  • Adverse Event Managers
  • Medical Affairs Managers

Webinar plus USB Audio Recording/Transcript
Learn more


add to cart

Webinar only
Learn more


add to cart

24/7 Encore plus USB Audio Recording/Transcript
Learn more


add to cart

24/7 Encore Presentation
Learn more


add to cart

USB Audio Recording/Transcript
Learn more


add to cart


Meet Your Presenter

Ricki Chase, M.S.

Executive Director
Lachman Consultant Services, Inc.

Ricki Chase, M.S. is an Executive Director at Lachman Consultant Services, Inc., where she supports clients in the pharmaceutical, medical device and combination products industries in quality system improvement, FDA readiness and 483 and warning letter remediation. Prior to her position at Lachman aMs. Chase was responsible for overseeing the inspection of foreign and domestic industries, import operations, recommendations and development of administrative and legal actions and leadership of District personnel.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone (703) 538-7600 | Fax (703) 538-7676 | Toll free (888) 838-5578 | Email customerservice@fdanews.com

© 2019 FDAnews